Caplin Point Laboratories held its board meeting on May 14, 2026, wherein the board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, declared an interim dividend, and fixed the record date for shareholder eligibility. The statutory audit was conducted by M/s Brahmayya & Co., Chartered Accountants, who issued an unmodified opinion on both standalone and consolidated financial statements.

Board Decisions

The board approved the following key resolutions at its meeting held on May 14, 2026:

Consolidated Financial Performance

Caplin Point Laboratories delivered strong consolidated financial performance for Q4 FY26 and the full year FY26. The following table summarises key metrics:

Other Consolidated Financial Highlights

• Cash Flow from Operations in 12M FY26 stood at ₹523 Crores vs ₹432 Crores in 12M FY25.
• Free Cash Flow is ₹275 Crores (after Capex investment of ₹248 Crores) in 12M FY26, compared to ₹241 Crores (after Capex investment of ₹191 Crores) in 12M FY25.
• Free Cash Reserves as at March 31, 2026 stood at ₹1,471 Crores; Total Liquid Assets at ₹2,726 Crores.
• Inventories as at March 31, 2026 stood at ₹429 Crores — 50% at warehouses close to the customer, 16% in transit, and 34% in India.
• Receivables stood at 136 days; excluding the foreign exchange rate impact on the closing date, receivables would have stood at 125 days.
• Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for 12M FY26 is approximately 79% and 21% respectively.
• Caplin Steriles Limited (CSL) revenue composition between Product Supply and Milestone + Profit Share for 12M FY26 is approximately 80% and 20% respectively.

Standalone Financial Performance

On a standalone basis, the company also reported healthy growth for the year ended March 31, 2026:

Long-Term Growth Track Record

The company's performance over the last 5 and 10 years reflects consistent compounding across key financial metrics:

Strategic Growth Initiatives

Caplin Point has allocated an enhanced Capex budget of approximately ₹1,000+ Crores for investment projects, with around 50% nearing completion and the balance to be incurred over the next 2–3 years. The Capex will be financed solely through internal accruals, and the company will remain net cash positive throughout the process. Key facility projects are summarised below:

Business Highlights — Emerging Markets

Caplin Point's Latin America business continued to deliver robust and profitable growth across multiple segments. In Mexico, the company received approvals for 25 products with a pipeline of 120+ products to be filed within the next 18 months; it also won 11 General and Oncology products for tender supply over the next 24 months, with a total value of $4 million. In Chile, the company holds 135+ product licences and won 15 products for tender supplies over the next 24 months with a total value of around $10 million; it plans to set up its own Quality Release Lab in Chile within the next 12–18 months. The company also entered Brand Marketing in the CNS segment across 3 markets in LatAm and launched Branded Pre-Filled Syringe products in the region.

Under its "China 2.0" strategy, Caplin Point signed partnerships with multiple Chinese companies, gaining access to 110+ approved ANDAs/MAs in the US and EU, with products being extended to all Latin American countries under Caplin's name. The Oncology facility at SIDCO Kakkalur completed its first regulatory inspection successfully, and the company acquired several ANDAs in the Oncology segment from third parties. The Vizag API unit received its manufacturing licence and completed validations for 4 APIs, with plans to complete validations for 12 more APIs before year-end. The Thervoy Oncology API unit is expected to be completed for validations by Q3 FY27, with first DMF filings planned in FY28. The company also awaits approvals from several Central American countries for its internally developed GLP-1 products, with plans to expand the GLP-1 range to other South American markets in FY28 (post patent expiry). Amaris Clinicals is progressing to increase clinical trials to 3 studies per month from the existing 2 studies per month.

Business Highlights — US & Regulated Markets

Caplin Steriles Limited (CSL) continued excellent growth across all parameters, with the current B2B and B2C split at 75% and 25% respectively. Caplin Point received 10 ANDA approvals in FY26 and acquired 15 ANDAs from third-party companies (including 5 in COL name), taking its ANDA tally to 59 — a jump of 25 ANDAs over FY25. CSL has filed 54 products (of which 32 are approved) in multiple non-US markets including Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi Arabia, and UAE, with plans to file 50+ products in these regions in the next 18 months. The company also expanded the capacity of IV Bag lines to 3X the current size.

The company entered the Blow Fill Seal (BFS) technology segment, with the first product development nearing completion, targeting Unit Dose Ophthalmics and Sterile Inhalation products, with a development pipeline of over 14 products. The COL-II facility construction is expected to be completed by December 2026 to house 5 Injectable, Ophthalmic and BFS lines, with provision to add 3 more lines. Caplin Steriles USA Inc (CSU) completed its first full year of operations with around $11 million in revenue and 26.2% EBITDA, achieving profitability and self-sustaining cashflow within its first year; CSU has launched 30 products to date and plans to launch 15 more in the current year. Caplin Group also plans to establish a separate retail arm in the US focused on Ophthalmic products, Unit Dose Ophthalmics, Inhalations, and Oral Solid products licensed from Chinese company partnerships.

Chairman's Commentary

Commenting on the performance, Mr. C.C. Paarthipan, Chairman, said:

"The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delivered strong financial performance, with sustained margins, healthy cash generation, and consistent growth across our key markets. The strength of our unique end-to-end business model is showcased clearly by the consistency of these numbers, at a larger base also. Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth. We remain debt-free and will continue to remain so."

Trading Window and Regulatory Filing

The trading window for Designated Persons commenced on April 1, 2026 and remained closed until May 16, 2026 (both days inclusive), in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The board meeting outcome was signed by Venkatram G, General Counsel & Company Secretary (Membership No. A23989), and submitted to both BSE Limited and the National Stock Exchange of India Ltd. on May 14, 2026. The company also confirmed that its outstanding qualified borrowings at both the start and end of the financial year stood at NIL.

Caplin Steriles Limited (CSL), a subsidiary of Caplin Point Laboratories , announced on May 05, 2026, that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP. The approval covers the 100 mg/mL formulation available in 10 mL, 50 mL, and 100 mL vials, representing a generic therapeutic equivalent of the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC (NDA 208418).

Approval Details

The following table summarises the key parameters of the USFDA approval received by Caplin Steriles Limited:

Therapeutic Indication and Market Size

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. According to IQVIA™ (IMS Health), Calcium Gluconate Injection USP (100 mg/mL in 10 mL, 50 mL and 100 mL Vials) recorded US sales of approximately $71 million for the 12-month period ending March 2026.

About Caplin Steriles Limited

Caplin Steriles Limited is a fast-growing sterile product manufacturing company approved by several regulatory agencies, including US FDA, EU-GMP, ANVISA, and INVIMA. Key highlights of CSL's regulatory and pipeline profile include:

• 54 ANDAs filed in the USA on its own and with partners, with 54 approvals (including acquired ANDAs) so far
• A portfolio of 55+ simple and complex Injectable and Ophthalmic products intended to be filed over the next 4 years
• Multiple products filed with several approvals in non-US markets including Australia, Canada, Mexico, Chile, UAE, Hong Kong, Malaysia, South Africa, and Saudi Arabia

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa, with state-of-the-art manufacturing facilities covering a complete range of finished dosage forms. The company has appeared on Forbes "Asia's 200 Best Under a Billion" list for 7 times in the last 10 years, and was awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

Caplin One Labs Limited (COL), another subsidiary of Caplin Point Laboratories Limited, is in the second year of its operations at its oncology unit in Kakkalur, with various ongoing projects in different stages of completion for generic and specialty products for both regulated and other markets. COL holds 5 approved ANDAs for Injectable products.